当前位置: X-MOL 学术Mol. Cancer › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
CAR-NK cells for gastrointestinal cancer immunotherapy: from bench to bedside
Molecular Cancer ( IF 27.7 ) Pub Date : 2024-10-23 , DOI: 10.1186/s12943-024-02151-3
Xingwang Zhu, Jieyun Xue, Hongzhou Jiang, Dongwei Xue

Gastrointestinal (GI) cancers represent a significant health burden worldwide. Their incidence continues to increase, and their management remains a clinical challenge. Chimeric antigen receptor (CAR) natural killer (NK) cells have emerged as a promising alternative to CAR-T cells for immunotherapy of GI cancers. Notably, CAR-NK cells offer several advantages, including reduced risk of graft-versus-host disease, lower cytokine release syndrome, and the ability to target cancer cells through both CAR-dependent and natural cytotoxic mechanisms. This review comprehensively discusses the development and applications of CAR-NK cells in the treatment of GI cancers. We explored various sources of NK cells, CAR design strategies, and the current state of CAR-NK cell therapy for GI cancers, highlighting recent preclinical and clinical trials. Additionally, we addressed existing challenges and propose potential strategies to enhance the efficacy and safety of CAR-NK cell therapy. Our findings highlight the potential of CAR-NK cells to revolutionize GI cancer treatment and pave the way for future clinical applications.

中文翻译:


用于胃肠道癌症免疫治疗的 CAR-NK 细胞:从实验室到床边



胃肠道 (GI) 癌症在世界范围内构成了巨大的健康负担。其发病率持续增加,其管理仍然是一个临床挑战。嵌合抗原受体 (CAR) 自然杀伤 (NK) 细胞已成为 CAR-T 细胞的一种有前途的替代品,用于胃肠道癌症的免疫治疗。值得注意的是,CAR-NK 细胞具有多种优势,包括降低移植物抗宿主病的风险、降低细胞因子释放综合征以及通过 CAR 依赖性和自然细胞毒性机制靶向癌细胞的能力。本文全面讨论了 CAR-NK 细胞在胃肠道癌症治疗中的发育和应用。我们探讨了 NK 细胞的各种来源、CAR 设计策略以及 CAR-NK 细胞疗法治疗胃肠道癌症的现状,重点介绍了最近的临床前和临床试验。此外,我们解决了现有挑战并提出了提高 CAR-NK 细胞疗法疗效和安全性的潜在策略。我们的研究结果强调了 CAR-NK 细胞彻底改变胃肠道癌症治疗并为未来临床应用铺平道路的潜力。
更新日期:2024-10-23
down
wechat
bug